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Abstract
Background: Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of
resistance and strategies against the resistance have not been elucidated. We examined the
potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-
tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer
cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo.
Methods: Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and
PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in
vitro. To examine the therapeutic effect of cisplatin and LY294002, individually or combination an
AsPC-1 tumor xenograft model was prepared for in vivo study.
Results: Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells.
LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the
combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated
DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/
Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth
in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable
side effects in mice treated with combination therapy.
Conclusion: Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin
resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may
resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for
achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy.
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Background
Prognosis of pancreatic cancer is very poor. Forty percent
of patients with pancreatic cancer show locally advanced
disease, 40% shows metastatic disease, and 20% have
resectable tumors. Even with radical surgery, the majority
of patients recur [1,2]. Therefore, irrespective of resection,
the key point for the treatment of pancreatic cancer is suc-
cessful chemotherapy.
Currently, gemcitabine is regarded as the standard and
only efficacious chemotherapeutic agent for advanced
pancreatic cancer, even though it shows modest results
and limited survival benefit [1-3]. When the first line of
chemotherapy fails, there is no second effective chemo-
therapeutic agent for pancreatic cancer, because pancre-
atic cancer shows drug resistance to other single
chemotherapeutics, such as platinum agents, topoisomer-
ase inhibitors, and taxanes. This chemoresistance is a
major therapeutic hurdle for patients with pancreatic can-
cer [4]. If a way can be found to overcome drug resistance,
that would have wide use in cases the chemotherapy for
pancreatic cancer. However, the molecular mechanism of
chemoresistance in pancreatic cancer has not been clari-
fied, though many theories have been discussed, such as
loss of p53 function, increased DNA adduct repair, and
overexpression of HER-2/new [5]. The phosphatidylinosi-
tol 3-kinase (PI3K)/Akt pathway has also been said one of
the candidates for clarifying the chemoresistance of cispl-
atin [5]. PI3K/Akt pathway plays an important role in cell
survival when cells are exposed to stimuli, such as with-
drawal of growth factor, ultraviolet radiation, matrix
detachment, cell cycle discordance, and DNA damage [6].
Akt is overexpressed in pancreatic cancer cells [7]. There-
fore, the PI3K/Akt pathway might be an important sur-
vival pathway in the resistance of chemotherapy in
patients with pancreatic cancer.
In establishing this theory, several studies have indicated
that LY294002, a signaling inhibitor of the PI3K/Akt path-
way, can modulate sensitivity to cancer chemotherapy in
vitro. Brognard et al. [8] has demonstrated that Akt activity
might promote therapeutic resistance in human non-
small cell lung cancer cells and that LY294002 greatly
potentiated chemotherapy-induced apoptosis in cells
with high Akt levels, but not in cells with low Akt levels.
Especially, Akt-mediated chemoresistance has been
reported widely in ovarian cancer cases [9-13]. Moreover,
LY294002 addition increased sensitivity of radiation and
inhibited clonogenic growth [14]. All of these findings
suggest the possibility of treating human malignancies
using the PI3K/Akt inhibitor LY294002.
In the present study, we examined the molecular mecha-
nism of resistance in chemotherapy. We choose cisplatin
as a representative chemotherapeutic agent because it
shows strong resistance for pancreatic cancer therapy,
although it has been widely used for the treatment of
many other cancer cases. We examined the effects of
LY294002 in vitro, especially targeting the induction of
apoptosis, as well as altered expression of phosphorylated
Akt. We also evaluated the biological effects of this agent
in vivo with mouse xenografts, testing the possibility that
LY294002 might be useful as an antitumor drug for use in
human pancreatic cancer.
Methods
Cell Culture and Cell Proliferation Assay
Human pancreatic cancer cell lines AsPC-1 and PANC-1
were used in this study. AsPC-1 and PANC-1 cells were
seeded at a density of 2 × 103 cells/well on 96-well culture
plates with complete culture medium and allowed to
adhere to the plate overnight, and then the cells were incu-
bated in the presence of LY294002 and/or cisplatin at var-
ious concentrations for 48 hours. Cell numbers were
determined by the absorbance of each well at 490 nm
using a MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium] assay kit (CellTiter 96®  Aqueous One Solution
Reagent (Promega, Madison, WI)) to examine the antitu-
mor effect of cisplatin and/or LY294002.
Immunoblotting
Cell lysates were prepared 6 hours after the treatment. Pro-
tein lysates were loaded (10 μg) and fractionated by 10%
polyacrylamide gel. Specific bands were then visualized
by western blotting using antibodies recognizing phos-
phorylated-Akt (Ser473), phosphorylated-Bad (Ser112),
cleaved caspase-3, and β-actin. Horseradish peroxidase-
conjugated goat antirabbit IgG was used as a secondary
antibody for enhanced chemiluminescence.
DNA Fragmentation Assay
We examined DNA fragmentation to assess apoptosis in
AsPC-1 and PANC-1 cells. Cells were plated in 96-well
plates 24 hours before treatment. DNA fragmentation was
evaluated by examination of cytoplasmic histone-associ-
ated DNA fragments (mononucleosomes and oligonucle-
osomes) 48 hours after treatment with cisplatin and/or
LY294002 using a Cell Death Detection ELISAPlus  kit
(Roche Molecular Biochemical, Indianapolis, IN) accord-
ing to the manufacturer's instructions.
The In Vivo Experiment
BALB/C nu/nu 6-wk-old male mice purchased from Japan
SLC, Inc., were used in this study. All mice were main-
tained under specific pathogen-free conditions at the
Center for Animal Experimentation, Kagawa University,
in accordance with the Guide for Animal Experimenta-
tion, Kagawa University. Mice received s.c. injection of 1 ×
106 AsPC-1 cells in the right flanks. Seven days after injec-Journal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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tion, mice were randomized into four groups (n = 7 mice/
group) to receive either vehicle (control), cisplatin (5 mg/
kg), LY294002 (25 mg/kg), or cisplatin plus LY294002
intraperitoneally (i.p.). Cisplatin was injected once/week
(total 3 times), and LY294002 was administered twice/
week (total 6 times)). Mice were sacrificed on day 28 after
tumor cell injections. Tumor growth was assessed weekly
by measuring the two greatest perpendicular tumor
dimensions. Tumor volume was calculated as follows:
tumor volume (mm3) = [tumor length (mm) × tumor
width (mm)2]/2 [15]. We measured the body weights and
serum albumin, total bilirubin, and creatinine levels to
examine the side effects.
Statistical Analyses
Multiple one-way analyses of variance (ANOVA) followed
by Scheffé's post hoc tests were used to assess differences
among groups. Results were considered significant for P <
0.05. Data were expressed as the mean ± SD of the mean.
Results
Growth inhibition of pancreatic cancer cells by cisplatin or 
LY294002
Overall cell growth of AsPC-1 and PANC-1 pancreatic can-
cer cells treated with cisplatin or LY294002 at different
concentrations ranging from 0.1 to 10 μmol/L and 1 to 50
μmol/L, respectively, were determined by MTS assay. As
shown in Figure 1, both agents inhibited cell growth in a
dose-dependent manner, and significant growth inhibi-
tion was demonstrated at the concentration of cisplatin
10 μmol/L and LY294002 50 μmol/L, 48 hours after treat-
ment.
Akt activation caused by cisplatin stimulation
Western blotting (Figure 2) shows the status of Akt activa-
tion using phospho-Akt antibody. Akt was phosphor-
ylated over the concentration 5 μmol/L of cisplatin in
both cell lines 6 hours after treatment. This phosphoryla-
tion was canceled by the addition of 10 μmol/L of
LY294002.
PI3 kinase inhibitor enhances the growth inhibitory effects 
of cisplatin
To evaluate the effect of LY294002 on cisplatin treatment
in pancreatic cancer cells, we evaluated cell proliferation
using the MTS assay. In this experiment we selected a dose
of 10 μmol/L of LY294002, which inhibited Akt phospho-
rylation caused by the stimulation of cisplatin in cell sur-
vival as shown in Figure 2. Augmentation of cisplatin with
LY294002 inhibited cell growth in both cell lines (Figure
3). Compared with treatment with cisplatin or LY294002
alone, the combination treatment inhibited cell prolifera-
tion and viability more significantly (P  < 0.05), 81%,
82%, 59% in AsPC-1 cells, and 81%, 83% and 61% in
PANC-1 cells compared from control, respectively.
Augmentation therapy with LY294002 enhanced the 
apoptotic pathway
Apoptosis is an important mechanism for antiprolifera-
tive activity of many naturally occurring agents as well as
synthetic agents. Apoptosis-induced treatment was
assessed by ELISA-based quantification of cytoplasmic
histone-associated DNA fragments. Treatment for 48
hours in AsPC-1 and PANC-1 cells with LY294002
resulted significant increase in the levels of cytoplasmic
histone-associated DNA fragments at the dose of 20
μmol/L when compared with the control. This increase
was not prominent in either cell line after receiving cispl-
atin treatment only (Figure 4A and 4B).
To examine the synergetic effect of cisplatin and
LY294002, we evaluated cell growth at doses of 1, 5, and
10 μmol/L of cisplatin under the presence of 10 μmol/L
LY294002, since the concentration was sufficient to
inhibit Akt activation. Interestingly, the augmentation
effect of LY294002 (at this concentration, LY294002
alone did not show significant apoptosis) in this apop-
totic assay was more significant (Figure 4) than cell
growth using the MTS assay (Figure 3) with 1.5 to 3 times
increased levels of apoptosis assessed by DNA fragmenta-
tion in AsPC-1 and PANC-1 cells.
Augmentation therapy modulates downstream effecters of 
Akt to apoptosis
There are multiple targets of the PI3K/Akt pathway that
may mediate the ability of this cascade to promote cell
survival during chemotherapy. Bad is a representative pro-
tein involved in cell death that has been shown to be reg-
ulated by Akt activity [13]. Upon activation of Akt, Bad is
phosphorylated, resulting in its inactivation and the pro-
motion of cell survival. As shown in Figure 5, phosphor-
ylated levels of Bad protein are only slightly increased
after the administration of cisplatin. However, combina-
tion therapy resulted in a lower phosphorylation level. In
addition, combination therapy exacerbated the cleavage
of caspase-3, an effecter of apoptosis, to a greater degree
than did a single treatment of cisplatin.
Synergetic effect of LY294002 on cisplatin therapy using 
mouse xenografts
A nude mouse model of pancreatic cancer was used to
assess the in vivo synergetic effect of LY294002. Cisplatin
at a dose of 5 mg/kg per week and LY294002 at a dose of
25 mg/kg twice/week were administered to mice bearing
established AsPC-1 tumors for 3 weeks. As shown in Fig-
ure 6, at day 21, the control group of mice showed an
increased tumor volume, while the group treated with cis-
platin or LY294002 showed a decreased tumor volume by
77% and 70% compared to the controls, respectively. In
addition, the combination treatment seemed to be more
effective than the respective single treatments. The growthJournal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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Growth inhibition of pancreatic cancer cells by cisplatin and/or LY294002 Figure 1
Growth inhibition of pancreatic cancer cells by cisplatin and/or LY294002. The antitumor growth effect of each single agent as 
well as the combination of agents was examined by MTS assay in 96-well plates at 2 × 103 cells/well. AsPC-1 and PANC-1 cells 
were cultured with cisplatin (0.1, 0.5, 1, 5, and 10 μmol/L) or LY294002 (1, 5, 10, 20, and 50 μmol/L) for 48 hours in DMEM-
10% FBS. AsPC-1 cells were treated with cisplatin (A-1) and LY294002 (A-2). PANC-1 cells were treated with cisplatin (B-1) 
and LY294002 (B-2). A dose-dependent effect of cisplatin and LY294002 can be seen in these diagrams. Values represent the 
means (± SD) of n = 5. P < 0.05 compared with the controls.Journal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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of tumor volume decreased to 44% of the volume in the
controls, which was a significant difference, (P < 0.05).
Side effects were not detected in combination therapy
To examine the side effect of combination therapy, the
body weights and serum albumin, total bilirubin, and cre-
atinine levels were examined at the end of therapy on day
28. No significant side effects were detected except for a
slight elevation of ALT level.
Discussion
All chemotherapeutic agents have inhibitory effect on
tumor growth in high doses in vitro, as shown in Figure
1A-1 and 1B-1, however, the most important factor for
successful chemotherapy in vivo is to think the safety range
between therapeutic and toxic doses. Therefore, the up-
regulation of chemosensitivity for cancer cells is impor-
tant for chemotherapy without toxic effects. The chemo-
sensitivity is defined by the intrinsic resistance which
originally exists before chemotherapy, and acquired resist-
ance which occurs during the period of chemotherapy. On
the other hand, cisplatin has revealed itself as one of the
most potent antitumor agents and has been applied to
Akt activation caused by cisplatin stimulation Figure 2
Akt activation caused by cisplatin stimulation. Western blot-
ting shows the status of Akt activation using phospho-Akt 
antibody. Akt was phosphorylated at cisplatin concentrations 
over 5 μmol/L in both cell lines 6 hours after treatment. This 
phosphorylation was blocked by the addition of 10 μmol/L of 
LY294002.
PI3-kinase inhibitor enhances the growth inhibitory effects of cisplatin Figure 3
PI3-kinase inhibitor enhances the growth inhibitory effects of cisplatin. Cell proliferation was measured by MTS assay. The 
combined administration of 10 μmol/L LY294002 and 5 μmol/L cisplatin inhibited cell growth in AsPC-1 (A) and PANC-1 (B) 
significantly. Values represent the means (± SD) of n = 5. *, + and # compared with control, cisplatin treatment and LY294002 
treatment group, respectively (P < 0.05).Journal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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Augmentation therapy of LY294002 enhanced the apoptotic pathway in pancreatic cancer Figure 4
Augmentation therapy of LY294002 enhanced the apoptotic pathway in pancreatic cancer. Cytoplasmic histone-associated 
DNA fragments were determined by ELISA-based quantification. The pathway was increased significantly 48 hours after 
LY294002 administration, but apoptosis was not prominent following cisplatin treatment in AsPC-1 cell lines (A). The addition 
of 10 μmol/L LY294002 increased apoptosis in the presence of cisplatin synergistically. PANC-1 cell lines showed the same 
results (B). Values represent the means (± SD) of n = 5. *, + and # compared with control, cisplatin treatment and LY294002 
treatment group, respectively (P < 0.05).Journal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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various human malignancies, such as cancers of the
esophagus, head, neck, and ovary in the last 30 years, but
cisplatin has not been found to be effective against pan-
creatic cancer [5]. Antitumor effect of cisplatin is based on
the inhibition of DNA synthesis and RNA transcription,
cell cycle arrest, and the induction of apoptotic pathways
[5]. If we can up-regulate the sensitivity of cisplatin to
pancreatic cancer cells, we will have a new therapeutic
option for pancreatic cancer. Therefore, we examined the
mechanism of the intrinsic resistance for cisplatin in pan-
creatic cancer cells. We found that (a) pancreatic cancer
cells activated the PI3K/Akt pathway against cisplatin
treatment; (b) inhibition of the PI3K/Akt pathway
enhanced the antitumor effect of cisplatin, and (c) cispla-
tin induced apoptosis with subsequent deactivation of
proapoptotic factors such as Bad and Caspace-3. Finally,
we demonstrated that a combination therapy of cisplatin
and LY294002 enhanced the antitumor effect in an in vivo
model.
The PI3K/Akt pathway is one of the core intracellular sig-
naling pathways in the stimulation of growth factors. Akt
expression or its phosphorylated form has been reported
as a significant prognosticator in sarcoma [16], gastric
cancer [17], pancreatic cancer [18], and breast cancer [19].
Therefore, inactivation of the PI3K/Akt pathway should
be effective as a specific chemotherapy against malignant
tumors [20,21] because of lower expression of Akt in the
surrounding normal tissue, and this type of chemotherapy
should not have strong side effects. In addition, Akt plays
an essential role as a survival signal pathway when cancer
cells are exposed to cellular stress such as heat shock, oxi-
dative stress, UV irradiation, matrix detachment, cell cycle
discordance, DNA damage, and antitumor drug adminis-
tration [22]. Therefore, DNA damage or reactive oxygen
species induced by cisplatin may contribute to cisplatin
resistance through the Akt activation [5].
Our data showed that Akt was up-regulated by cisplatin
stimulation to prevent apoptosis. Therefore, inhibition of
PI3K/Akt is a rational strategy against cancer cells to
escape from cell death by cisplatin therapy. Several down-
stream effectors have been reported in PI3K/Akt phospho-
rylation-mediated cell survival. Bad, which is a pro-
apoptotic Bcl-2 family member, can mediate cell survival
by Akt phosphorylation [13]. Phosphorylated Akt can
directly phosphorylate Bad, and may render Bad incapa-
ble of binding to Bcl-XL and restore the antiapoptotic
function of Bcl-2, and regulate the activation of caspases
through control of cytochrome c release from the mito-
chondria [23]. Our data also supported this pathway as a
possible mechanism of cisplatin resistance. This form of
cell death and apoptosis is a complex and well-organized
process. The cytotoxicity of cisplatin activates many other
signal transduction pathways, such as Fas/FasR, ATR, p53,
and MAPK, and culminates in the activation of apoptosis
through caspace-3 activation [5,24,25]. On the other
hand, many biological defense systems are activated
against this apoptotic stimulation, such as overexpression
of HER-2/neu, loss of p53 function, and overexpression of
antiapoptotic bcl-2 [5,26].
Many studies have been documented that LY294002 has
a strong antitumor activity by inhibiting the PI3K/Akt
pathway. However the majority of these studies were in
vitro studies. The most important finding in the present
study was in the in vivo experiment of pancreatic cancer
therapy using cisplatin and LY294002. Also we examined
the well tolerated toxicity of LY294002 because high dose
of PI3K/Akt inhibitors interfere with the survival and/or
proliferation of critical populations of normal cells and
would display unacceptable toxicity when the PI3K/Akt
pathway plays a critical role in many aspects of normal
cellular homeostasis. Hu et al [27]. reported that daily i.p.
administration of LY294002 at a dose of 100 mg/kg
caused body weight loss and dry scaly skin in mice with
ovarian cancer, presumably as a result of increased epider-
mal cell apoptosis that resulted in hyperkeratosis. There-
fore, in the following study, they decreased shots of
LY294002 administration to 3 days per week in combina-
tion with pacritaxel in ovarian cancer xenografts model
within acceptable side effects [13]. Our results also
showed similar result that twice a week i.p. administration
of 25 mg/kg LY294002 was well tolerated.
In conclusion, the present study show that the combina-
tion of cisplatin and LY294002 has an additive or syner-
Augmentation therapy modulates downstream effecters of  Akt to apoptosis Figure 5
Augmentation therapy modulates downstream 
effecters of Akt to apoptosis. The downstream effects of 
the Akt pathway were examined by Western blotting. Bad 
was phosphorylated by cisplatin (5 μmol/L) treatment, while 
LY294002 (10 μmol/L) inhibited the phosphorylation. Aug-
mentation with LY294002 weakened Bad phosphorylation 
and increased the cleavage of caspases-3.Journal of Experimental & Clinical Cancer Research 2008, 27:76 http://www.jeccr.com/content/27/1/76
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Synergetic effect of LY294002 on cisplatin therapy using mouse xenografts Figure 6
Synergetic effect of LY294002 on cisplatin therapy using mouse xenografts. AsPC-1 xenograft nude mice were 
treated with cisplatin and/or LY294002 for 3 weeks. Tumor volume in the mice administrated (i.p.) with cisplatin or LY294002 
was slowly inhibited compared with the controls. Combination therapy showed significant inhibition compared to the results of 
single-agent treatments. Values represent the means (± SD) of n = 7. *, + and # compared with control, cisplatin treatment and 
LY294002 treatment group, respectively (P < 0.05).
Table 1: Side effects in combination therapy at the point of sacrifice.
Control Cisplatin (5 mg/kg) LY294002 (25 mg/kg) Cisplatin (5 mg/kg) + LY294002 (25 mg/kg)
Body weight (g) 23.7 ± 0.8 23.6 ± 0.5 23.8 ± 0.7 23.7 ± 0.8
Serum albumin (g/dl) 3.2 ± 0.2 3.1 ± 0.2 3.1 ± 0.3 3.2 ± 0.2
Total bilirubin (mg/dl) 0.04 ± 0.02 0.05 ± 0.01 0.06 ± 0.01 0.04 ± 0.02
Creatinine (mg/dl) 0.05 ± 0.02 0.06 ± 0.02 0.08 ± 0.02 0.05 ± 0.03
ALT (IU/l) 34.1 ± 9.7 31.5 ± 5.6 30.0 ± 6.7 44.1 ± 9.7 *
This table shows the body weights and serum albumin, total bilirubin, and creatinine levels at the end of therapy on day 28 in vivo experiments. No 
significant side effects were detected except for a slight elevation of ALT level in the combination therapy group. Values represent the means (± SD) 
of n = 7. P < 0.05 compared with LY294002 treatment group.Publish with BioMed Central    and   every 
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gistic effect both in vivo and  in vitro against human
xenografts, i.e., an antitumor activity greater than that of
each drug used as a single agent at the maximum tolerated
dose. Our result presents a rational combination therapy
based on the up-regulation of sensitivity for cisplatin and
suggests a new strategy, the sensitization of pancreatic
cancer to cisplatin, and provides a new application of an
anticancer drug that has been considered non-effective.
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